Liraglutide
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Novo Nordisk · Phase 2 · Completed · Enrollment 834
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| MEDI0382 low dose + Metformin | n/r | n/r | n/r | n/r | n/r |
| MEDI0382 mid dose + Metformin | n/r | n/r | n/r | n/r | n/r |
| MEDI0382 high dose + Metformin | n/r | n/r | n/r | n/r | n/r |
| Placebo + Metformin | 12 participants | 5 participants | 10 participants | n/r | 0 |
| Liraglutide + Metformin | 17 participants | 3 participants | 4 participants | n/r | 0 |
| MEDI0382 100 mcg | 23 participants | 10 participants | 13 participants | n/r | 0 |
| MEDI0382 200 mcg | 85 participants | 51 participants | 49 participants | n/r | 2 |
| MEDI0382 300 mcg | 105 participants | 43 participants | 28 participants | n/r | 1 |
A count stays a count. This page does not turn a count into a percent.